Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

First Widely Available Zika Test Ok’d for Emergency Use

By Drug Discovery Trends Editor | May 2, 2016

In this Thursday, Feb. 4, 2016, file photo, a medical researcher uses a monitor that shows the results of blood tests for various diseases, including Zika, at the Gorgas Memorial laboratory in Panama City. On Thursday, April 28, 2016, the U.S. Food and Drug Administration authorized Quest Diagnostics to offer the first commercial test for the Zika virus in the United States. Previously, Zika tests were only available through a handful of government-designated laboratories. Quest said the commercial test could be available as early as the first week of May. (AP Photo/Arnulfo Franco)The first commercial test for the Zika virus has been cleared for emergency use in the U.S. and could be available by next week.

The Food and Drug Administration granted the authorization Thursday to the test’s developer, Quest Diagnostics, which said it would make it widely available to doctors for patient testing.

The company said the test results will initially be processed at a laboratory in San Juan Capistrano, California, which developed and validated the technology.

Eventually the test could be expanded to several dozen other Quest laboratories throughout the U.S. and in Puerto Rico. Previously Zika tests were only available through a handful of government-designated laboratories.

The new test detects genetic material known as RNA from the Zika virus in human blood serum.

Zika has become epidemic in Latin America and the Caribbean since last fall. The virus is mainly spread through mosquito bites and causes mild illness or no symptoms in most people. But it can cause microcephaly, a severe birth defect in which babies are born with abnormally small heads.

There have been 426 cases of Zika reported in the U.S. – all linked to travel to outbreak areas. But officials think it’s likely some small clusters of Zika infections will occur in the U.S. when mosquito numbers boom.

The virus is spreading quickly across Puerto Rico and officials there recorded the first Zika-related U.S. death on Friday. Zika-related deaths in adults are considered extremely rare.

The U.S. territory is battling more than 700 Zika cases and seeks federal funds to help prevent an epidemic at a time of worsening economic crisis.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE